An Open-label, Dose Escalating Phase Ib Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of GLPG0187 in Subjects With Solid Tumors.

Trial Profile

An Open-label, Dose Escalating Phase Ib Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of GLPG0187 in Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2016

At a glance

  • Drugs GLPG 0187 (Primary)
  • Indications Glioblastoma; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors Galapagos NV
  • Most Recent Events

    • 20 Jan 2016 Results published in the Investigational New Drugs.
    • 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Mar 2013 Enrolment of patients has been completed; based on positive results and following requests of the investigators, additional patients will be included in this study, according to a Galapagos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top